Biogen Trims Pipeline Programs To Cut Costs, Focus On Alzheimer's Drug Launch

Biogen Inc said on Tuesday it will pause or discontinue at least four studies of experimental drugs to focus on more potentially lucrative options including its second Alzheimer's treatment, Leqembi,

Related Keywords

Myles Minter , William Blair , Christopher Viehbacker , Michael Mcdonnell , Drug Administration On , Biogen Inc , Executive Christopher Viehbacker , Chief Financial Officer Michael , Drug Administration , Business , ,